"# Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ: A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology. 2007 Oct;53(5):638-42. Epub 2007 Aug 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17845807 # Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A: The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther. 2004 Feb;308(2):583-90. Epub 2003 Nov 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14610233 # Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W: Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13129693"@en . . "Pralnacasan inhibits interleukin-1beta converting enzyme (ICE), an enzyme that regulates the production of IL-1 and IFN gamma - intercellular mediators that initiate and sustain the process of inflammation. Inhibiting ICE may be an effective strategy for curtailing damaging inflammatory processes common to a number of acute and chronic conditions, such as rheumatoid arthritis (RA) and osteoarthritis."@en . . . "Orally bioavailable"@en . . . . "Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE)."@en . "For the treatment of rheumatoid arthritis (RA)."@en . . "HMR 3480"@en . . . . . . . "investigational"@en . . . . . "Humans and other mammals"@en . . . . "Pralnacasan"@en . . "192755-52-5"@en . . . . . . . . . . . . .